FDA issues new Draft Guidance on Communication between Sponsors and FDA

Best Practices for Communication Between IND Sponsors and FDA During Drug Development-Guidance for Industry and Review Staff

The purpose of this guidance is to describe best practices and procedures for timely, transparent, and effective communications between investigational new drug application (IND) sponsors and FDA at critical junctures in drug development, which may facilitate earlier availability of safe and effective drugs to the American public. This guidance describes:

  • FDA’s philosophy regarding timely interactive communication with IND sponsors as a core activity
  • The scope of appropriate interactions between the review team and the sponsor
  • The types of advice appropriate for sponsors to seek from FDA in pursuing their drug development program
  • General expectations for the timing of FDA response to IND sponsor inquiries
  • Best practices and communication methods to facilitate interactions between the FDA review team and the IND sponsor during drug development
  • Expectations for appropriate methods, including the frequency, of such communications
Read the pdf
Copyright Widler & Schiemann AG 2015. All Rights Reserved. /